Barinthus Biotherapeutics (BRNS) Change in Cash (2020 - 2026)

Barinthus Biotherapeutics has reported Change in Cash for 7 years, with the latest figure at -$4.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 60.55% year-over-year to -$4.7 million; the trailing twelve-month figure through Mar 2026 stood at -$33.4 million (down 13.6% YoY), and the FY2025 full-year result was -$40.5 million, down 36.57% from the prior year.
• Change in Cash for Q1 2026 stood at -$4.7 million, down from -$3.8 million in the prior quarter.
• The five-year high for Change in Cash was $7.8 million in Q3 2022, with the low at -$18.3 million in Q2 2023.
• Historically, Change in Cash has averaged -$8.6 million across 5 years, with a median of -$11.8 million in 2025.
• Annual changes were most pronounced in 2022 — Change in Cash soared 179.78% — and 2024, when it slumped 296.43%.
• Barinthus Biotherapeutics' Change in Cash stood at -$5.7 million in 2022, then tumbled by 218.57% to -$18.2 million in 2023, then jumped by 134.57% to $6.3 million in 2024, then sank by 160.69% to -$3.8 million in 2025, then declined by 22.0% to -$4.7 million in 2026.
• The last three Change in Cash figures came in at -$4.7 million (Q1 2026), -$3.8 million (Q4 2025), and -$12.1 million (Q3 2025), per Business Quant data.